These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

410 related items for PubMed ID: 23050510

  • 1. The FDA's assessment of two drugs for chronic weight management.
    Colman E, Golden J, Roberts M, Egan A, Weaver J, Rosebraugh C.
    N Engl J Med; 2012 Oct 25; 367(17):1577-9. PubMed ID: 23050510
    [No Abstract] [Full Text] [Related]

  • 2. 2 new drugs for weight loss.
    Med Lett Drugs Ther; 2012 Sep 03; 54(1398):69-71. PubMed ID: 22992487
    [No Abstract] [Full Text] [Related]

  • 3. Two anti-obesity hopefuls and their safety.
    Bello NT, Campbell SC.
    Expert Opin Drug Saf; 2012 Sep 03; 11(5):681-3. PubMed ID: 22788876
    [No Abstract] [Full Text] [Related]

  • 4. Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease.
    Bays H.
    Expert Rev Cardiovasc Ther; 2010 Dec 03; 8(12):1777-801. PubMed ID: 20707765
    [Abstract] [Full Text] [Related]

  • 5. New antiobesity agents: lorcaserin (Belviq) and phentermine/topiramate ER (Qsymia).
    Shyh G, Cheng-Lai A.
    Cardiol Rev; 2014 Dec 03; 22(1):43-50. PubMed ID: 24304809
    [Abstract] [Full Text] [Related]

  • 6. Two new drugs approved for obesity.
    Johnson AM.
    S D Med; 2012 Sep 03; 65(9):356-7. PubMed ID: 23066610
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Obesity Epidemic: Pharmaceutical Weight Loss.
    Curry SA.
    R I Med J (2013); 2017 Mar 01; 100(2):18-20. PubMed ID: 28246654
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The FDA's risk/benefit calculus in the approvals of Qsymia and Belviq: treating an obesity epidemic while avoiding another fen-phen.
    Azebu LM.
    Food Drug Law J; 2014 Mar 01; 69(1):87-111, ii-iii. PubMed ID: 24772687
    [Abstract] [Full Text] [Related]

  • 14. Unambiguous identification of obesity trials.
    Zarin DA, Tse T.
    N Engl J Med; 2013 Feb 07; 368(6):580-1. PubMed ID: 23388022
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Combination phentermine/topiramate for obesity treatment in primary care: a review.
    Xiong GL, Gadde KM.
    Postgrad Med; 2014 Mar 07; 126(2):110-6. PubMed ID: 24685974
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The new weight-loss drugs, lorcaserin and phentermine-topiramate: slim pickings?
    Woloshin S, Schwartz LM.
    JAMA Intern Med; 2014 Apr 07; 174(4):615-9. PubMed ID: 24515599
    [Abstract] [Full Text] [Related]

  • 19. Formulary management of 2 new agents: lorcaserin and phentermine/topiramate for weight loss.
    Kelly EM, Tungol AA, Wesolowicz LA.
    J Manag Care Pharm; 2013 Oct 07; 19(8):642-54. PubMed ID: 24074010
    [Abstract] [Full Text] [Related]

  • 20. Lemons for obesity.
    Lauer MS.
    Ann Intern Med; 2012 Jul 17; 157(2):139-40. PubMed ID: 22801677
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.